Document Detail

The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion.
MedLine Citation:
PMID:  1531789     Owner:  NLM     Status:  MEDLINE    
The role of the rate of increase in hematocrit (Hct) and changes in vasoactive substances as a cause of hypertension induced by the administration of recombinant erythropoietin (r-EPO) were examined in 20 stable hemodialysis (HD) patients. Measurements were made twice at the start of treatment and when the Hct reached 30%. Patients were divided into 2 groups: Group I: 14 patients received r-EPO, 3000 units intravenously three times a week. Group II: 6 patients, needing repeated blood transfusion, were given 2 to 4 units of washed red blood cells during a HD session. The Hct increased by 0.65%/week in Group I and by 6.7%/2 days in Group II. An elevation in blood pressure was not seen in any patient. There was no difference in the levels of renin, angiotensin II, epinephrine, norepinephrine, dopamine, atrial natiuretic peptide (ANP), BUN, creatinine, cardiac thoracic ratio and body weight in any of the groups. In conclusion, elevation of the Hct in HD patients whatever the rate of increase within the 30% Hct range, does not cause an increase in blood pressure. In addition, the levels of vasoactive substances do not change in partially corrected anemic HD patients. As a result blood pressure control can be helped by aiming at the lower target Hct level of around 30%.
K Ono; Y Hisasue
Related Documents :
7883579 - Effectiveness of assistance circulations for distal circulatory support during cross-cl...
24403609 - Role of turgor pressure in endocytosis in fission yeast.
15244189 - Comparison of the experimental intestinal anastomoses performed by different surgeons.
15278489 - Sustained effects of plasma norepinephrine levels on femoral-radial pressure gradient a...
11605939 - Desflurane confers neurologic protection for deep hypothermic circulatory arrest in new...
2522279 - Pericardial pressure attenuates release of atriopeptin in volume-expanded dogs.
25419829 - Circuit oxygenator contributes to extracorporeal membrane oxygenation-induced hemolysis.
10373099 - Development of inverse circadian blood pressure pattern in transgenic hypertensive tgr(...
19868789 - The effect of peptone on the peripheral circulation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical nephrology     Volume:  37     ISSN:  0301-0430     ISO Abbreviation:  Clin. Nephrol.     Publication Date:  1992 Jan 
Date Detail:
Created Date:  1992-04-09     Completed Date:  1992-04-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0364441     Medline TA:  Clin Nephrol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  23-7     Citation Subset:  IM    
Ono Geka Clinic, Fukuoka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / blood
Atrial Natriuretic Factor / blood
Blood Pressure* / physiology
Blood Transfusion*
Catecholamines / blood*
Dopamine / blood
Epinephrine / blood
Erythropoietin / administration & dosage,  therapeutic use*
Hypertension / etiology
Injections, Intravenous
Kidney Failure, Chronic / therapy
Middle Aged
Norepinephrine / blood
Pilot Projects
Recombinant Proteins
Renal Dialysis*
Renin / blood
Reg. No./Substance:
0/Catecholamines; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 11128-99-7/Angiotensin II; 51-41-2/Norepinephrine; 51-43-4/Epinephrine; 85637-73-6/Atrial Natriuretic Factor; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pathogenic autoantibody-inducing gamma/delta T helper cells from patients with lupus nephritis expre...
Next Document:  Regression of left ventricular mass in systemic hypertension.